Royalty Pharma (RPRX) Cash from Investing Activities (2019 - 2026)

Royalty Pharma has disclosed Cash from Investing Activities across 8 years of filings, most recently posting -$229.7 million for Q2 2026.

• In Q2 2026, Cash from Investing Activities rose 26.37% year-over-year to -$229.7 million; the TTM figure through Jun 2026 stood at -$2.5 billion (down 66.87% YoY), while the FY2025 annual figure was -$1.6 billion, up 39.73% from the prior year.
• Cash from Investing Activities came in at -$229.7 million for Q2 2026 at Royalty Pharma, up from -$477.9 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $503.9 million in Q1 2025 to a low of -$1.4 billion in Q3 2022.
• Average Cash from Investing Activities over 5 years is -$450.1 million, with a median of -$464.3 million recorded in 2023.
• Year-over-year, Cash from Investing Activities tumbled 5102.47% in 2023 and jumped 681.55% in 2025.
• Over 5 years, Cash from Investing Activities stood at $414.7 million in 2022, then sank by 341.16% to -$1.0 billion in 2023, then jumped by 49.45% to -$505.6 million in 2024, then tumbled by 67.69% to -$847.8 million in 2025, then jumped by 72.9% to -$229.7 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$229.7 million in Q2 2026, -$477.9 million in Q1 2026, and -$847.8 million in Q4 2025.